Literature DB >> 12374096

The herpesvirus encoded dUTPase as a potential chemotherapeutic target.

A W Studebaker1, G K Balendiran, M V Williams.   

Abstract

The human herpesviruses are a well characterized group of viruses that are responsible for a wide spectrum of human diseases. Included in this group of pathogens are the alphaherpesviruses (herpes simplex types 1 and 2 and varicella-zoster virus), the betaherpesviruses (cytomegalovirus, human herpesvirus types 6 and 7) and the gammaherpesviruses (Epstein-Barr virus and human herpesvirus 8). An important feature of these viruses is that they cause latent infections that can be reactivated to cause disease. The herpesviruses encode for a large number of structural and non-structural proteins, and several of the non-structural proteins, such as thymidine kinase, DNA polymerase, and ribonucleotide reductase, have been utilized as targets for the development of anti-herpesvirus agents. Another herpesvirus encoded enzyme that has received little attention as a potential target for the development of specific anti-herpesvirus agents is deoxyuridine triphosphate nucleotidohydrolase (dUTPase). Furthermore, little is known concerning the role of the herpesviruses' encoded dUTPases in virus replication and in modulating the chemotherapeutic efficiency of other anti-herpes agents. Because of recent advances in molecular virology and biochemistry, it is now possible to rationally develop "designer" drugs based upon the structural/functional interaction of the drug with a specific viral protein. The purpose of this review is to describe previous studies demonstrating the potential use of the herpesvirus encoded dUTPase as a drug target, to describe problems associated with using the dUTPase as a target and to discuss new approaches that can be used.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12374096     DOI: 10.2174/1389203013380946

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  5 in total

1.  X4 and R5 HIV-1 have distinct post-entry requirements for uracil DNA glycosylase during infection of primary cells.

Authors:  Kate L Jones; Michael Roche; Michael P Gantier; Nasim A Begum; Tasuku Honjo; Salvatore Caradonna; Bryan R G Williams; Johnson Mak
Journal:  J Biol Chem       Date:  2010-04-06       Impact factor: 5.157

2.  Uracil-directed ligand tethering: an efficient strategy for uracil DNA glycosylase (UNG) inhibitor development.

Authors:  Yu Lin Jiang; Daniel J Krosky; Lauren Seiple; James T Stivers
Journal:  J Am Chem Soc       Date:  2005-12-14       Impact factor: 15.419

3.  The simian varicella virus uracil DNA glycosylase and dUTPase genes are expressed in vivo, but are non-essential for replication in cell culture.

Authors:  Toby M Ward; Marshall V Williams; Vicki Traina-Dorge; Wayne L Gray
Journal:  Virus Res       Date:  2009-02-04       Impact factor: 3.303

4.  Linking uracil base excision repair and 5-fluorouracil toxicity in yeast.

Authors:  Lauren Seiple; Pawel Jaruga; Miral Dizdaroglu; James T Stivers
Journal:  Nucleic Acids Res       Date:  2006-01-10       Impact factor: 16.971

Review 5.  Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases.

Authors:  An R Van Rompay; Magnus Johansson; Anna Karlsson
Journal:  Pharmacol Ther       Date:  2003-11       Impact factor: 12.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.